Lilly’s Mounjaro Diabetes Approval Is First Challenge To Novo’s GLP-1 Franchise
Tirzepatide Showed Superiority To Ozempic In Clinical Trials
Executive Summary
The GLP-1/GIP agonist tirzepatide is a key addition to Lilly’s commercial portfolio as the company leans on new products to deliver on volume-driven growth through the current decade.
You may also be interested in...
Weight Watchers Weighs In On Obesity Drugs, Offering Valuable Validation
WW International’s decision to move into pharmaceutical weight management could build commercial momentum for Novo Nordisk’s Wegovy and Lilly’s Mounjaro.
Five Clinical Trial Hits Of 2022
Any given year sees a variety of clinical trials produce positive or negative results. But some of those trials are especially important either for moving a field forward or for a company’s overall development and commercial strategy. Here, Scrip looks at some of the more notable trial successes of the last year.
J.P. Morgan Day Four: Talking With Execs About BD Plans
Daily notebook from the J.P. Morgan Healthcare Conference: Big pharma execs weigh in on business development strategy, Sage CEO Barry Green discusses how the Inflation Reduction Act should spur deal-making and bluebird talks about gene therapy commercialization plans.